KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EBIT (2019 - 2025)

Historic EBIT for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $427.2 million.

  • Royalty Pharma's EBIT fell 4188.94% to $427.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 72.39%. This contributed to the annual value of $1.3 billion for FY2024, which is 1338.38% down from last year.
  • Latest data reveals that Royalty Pharma reported EBIT of $427.2 million as of Q3 2025, which was down 4188.94% from $209.8 million recorded in Q2 2025.
  • Royalty Pharma's EBIT's 5-year high stood at $744.9 million during Q2 2021, with a 5-year trough of -$482.7 million in Q4 2022.
  • Moreover, its 5-year median value for EBIT was $269.6 million (2024), whereas its average is $299.7 million.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 41460.33% in 2022, then surged by 82407.89% in 2025.
  • Over the past 5 years, Royalty Pharma's EBIT (Quarter) stood at $153.4 million in 2021, then tumbled by 414.6% to -$482.7 million in 2022, then soared by 226.98% to $612.9 million in 2023, then tumbled by 41.02% to $361.5 million in 2024, then grew by 18.16% to $427.2 million in 2025.
  • Its EBIT stands at $427.2 million for Q3 2025, versus $209.8 million for Q2 2025 and $534.2 million for Q1 2025.